Lantheus Holdings Insider Sells $2M Worth of Shares

Lantheus Holdings, a radiopharmaceutical company, has reported that an insider sold shares worth $2,002,570, according to a recent SEC filing. The company's products are categorized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships, focusing on cancer diagnosis and treatment, cardiovascular disease diagnosis, and precision medicine. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and its pipeline includes NAV-4694 and pre-clinical assets TROP2 and DUNP19.

Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company, has reported that an insider sold shares worth $2,002,570, according to a recent SEC filing. The insider, identified as CFO Robert J. Jr. Marshall, sold 10,000 shares of the company's stock on March 17, 2025, at an average price of $100.52 per share.

The company's products are categorized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships, focusing on cancer diagnosis and treatment, cardiovascular disease diagnosis, and precision medicine. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and its pipeline includes NAV-4694 and pre-clinical assets TROP2 and DUNP19.

The insider sale follows a period of significant institutional investment in Lantheus Holdings. J2 Capital Management Inc. bought 4,068 shares of the medical equipment provider's stock during the first quarter, valued at approximately $397,000 [1]. Other large investors also modified their holdings of LNTH, with the State of New Jersey Common Pension Fund D boosting its position by 0.4% during the fourth quarter, and Bleakley Financial Group LLC growing its holdings by 6.1% during the same period [1].

Shares of Lantheus Holdings traded up $2.02 on Wednesday, hitting $79.71, following the insider sale. The stock had a trading volume of 459,291 shares, compared to its average volume of 991,854. The company has a market capitalization of $5.51 billion, a PE ratio of 13.26, and a beta of 0.23. The firm's fifty-day moving average is $91.26, and its 200-day moving average is $91.71 [1].

In other news, Lantheus Holdings reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. The firm had a net margin of 28.57% and a return on equity of 44.29%. The business's quarterly revenue was up 0.8% compared to the same quarter last year [1].

References:
[1] https://www.marketbeat.com/instant-alerts/filing-4068-shares-in-lantheus-holdings-inc-nasdaqlnth-acquired-by-j2-capital-management-inc-2025-05-31/